IGFBP2 potentiates nuclear EGFR-STAT3 signaling

Oncogene

Volumn 35, Issue 6, 2016, Pages 738-747

  Chua, C Y ^a,b   Liu, Y ^a,c   Granberg, K J ^a,d   Hu, L ^a   Haapasalo, H ^d   Annala, M J ^a,d   Cogdell, D E ^a   Verploegen, M ^a,e   Moore, L M ^a   Fuller, G N ^a,b,c   Nykter, M ^d   Cavenee, W K ^f   Zhang, W ^a,b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Cancer Genome Atlas   (United States)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; SOMATOMEDIN BINDING PROTEIN 2; STAT3 PROTEIN; EGFR PROTEIN, HUMAN; IGFBP-2 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ARTICLE; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSACTIVATION; ACTIVE TRANSPORT; BRAIN TUMOR; CELL CULTURE; CELL NUCLEUS; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; METABOLISM; MORTALITY; PATHOLOGY; PHYSIOLOGY; PROTEIN TRANSPORT; TRANSCRIPTION INITIATION;

ACTIVE TRANSPORT, CELL NUCLEUS; BRAIN NEOPLASMS; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION;

EID: 84958049422     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.131     Document Type: Article

References (96)

1. Dobrowolski R, De Robertis EM. Endocytic control of growth factor signalling: multivesicular bodies as signalling organelles. Nat Rev Mol Cell Biol 2012; 13: 53-60.
2. Sorkin A, Von Zastrow M. Signal transduction and endocytosis: close encounters of many kinds. Nat Rev Mol Cell Biol 2002; 3: 600-614.
3. Sorkin A, von Zastrow M. Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol 2009; 10: 609-622.
4. McMahon HT, Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol 2011; 12: 517-533.
5. Baxter RC. Insulin-like growth factor binding protein-3 (IGFBP-3): Novel ligands mediate unexpected functions. J Cell Commun Signal 2013; 7: 179-189.
6. Joy A, Moffett J, Neary K, Mordechai E, Stachowiak EK, Coons S et al. Nuclear accumulation of FGF-2 is associated with proliferation of human astrocytes and glioma cells. Oncogene 1997; 14: 171-183.
7. Stachowiak MK, Fang X, Myers JM, Dunham SM, Berezney R, Maher PA et al. Integrative nuclear FGFR1 signaling (INFS) as a part of a universal "feed-forwardand-gate" signaling module that controls cell growth and differentiation. J Cell Biochem 2003; 90: 662-691.
8. Arese M, Chen Y, Florkiewicz RZ, Gualandris A, Shen B, Rifkin DB. Nuclear activities of basic fibroblast growth factor: potentiation of low-serum growth mediated by natural or chimeric nuclear localization signals. Mol Biol Cell 1999; 10: 1429-1444.
9. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3: 802-808.
10. Sarfstein R, Werner H. Minireview: nuclear insulin and insulin-like growth factor-1 receptors: a novel paradigm in signal transduction. Endocrinology 2013; 154: 1672-1679.
11. Rakowicz-Szulczynska EM, Rodeck U, Herlyn M, Koprowski H. Chromatin binding of epidermal growth factor, nerve growth factor, and platelet-derived growth factor in cells bearing the appropriate surface receptors. Proc Natl Acad Sci USA 1986; 83: 3728-3732.
12. Baxter RC. Circulating binding proteins for the insulinlike growth factors. Trends Endocrinol Metab 1993; 4: 91-96.
13. Clemmons DR. Insulinlike growth factor binding proteins. Trends Endocrinol Metab 1990; 1: 412-417.
14. Scharf J, Ramadori G, Braulke T, Hartmann H. Synthesis of insulinlike growth factor binding proteins and of the acid-labile subunit in primary cultures of rat hepatocytes, of Kupffer cells, and in cocultures: regulation by insulin, insulinlike growth factor, and growth hormone. Hepatology 1996; 23: 818-827.
15. Holmes KM, Annala M, Chua CY, Dunlap SM, Liu Y, Hugen N et al. Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-kappaB network. Proc Natl Acad Sci USA 2012; 109: 3475-3480.
16. Wang GK, Hu L, Fuller GN, Zhang W. An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem 2006; 281: 14085-14091.
17. Pereira JJ, Meyer T, Docherty SE, Reid HH, Marshall J, Thompson EW et al. Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res 2004; 64: 977-984.
18. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 2007; 104: 5563-5568.
19. Han S, Li Z, Master LM, Master ZW, Wu A. Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin beta1-ERK pathway. Br J Cancer 2014; 111: 1400-1409.
20. Azar WJ, Azar SH, Higgins S, Hu JF, Hoffman AR, Newgreen DF et al. IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells. Endocrinology 2011; 152: 3332-3342.
21. Terrien X, Bonvin E, Corroyer S, Tabary O, Clement A, Henrion Caude A. Intracellular colocalization and interaction of IGF-binding protein-2 with the cyclin-dependent kinase inhibitor p21CIP1/WAF1 during growth inhibition. Biochem J 2005; 392: 457-465.
22. Miyako K, Cobb LJ, Francis M, Huang A, Peng B, Pintar JE et al. PAPA-1 Is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions. Mol Endocrinol 2009; 23: 169-175.
23. Hoeflich A, Reisinger R, Schuett BS, Elmlinger MW, Russo VC, Vargas GA et al. Peri/nuclear localization of intact insulin-like growth factor binding protein-2 and a distinct carboxyl-terminal IGFBP-2 fragment in vivo. Biochem Biophys Res Commun 2004; 324: 705-710.
24. Besnard V, Corroyer S, Trugnan G, Chadelat K, Nabeyrat E, Cazals V et al. Distinct patterns of insulin-like growth factor binding protein (IGFBP)-2 and IGFBP-3 expression in oxidant exposed lung epithelial cells. Biochim Biophys Acta 2001; 1538: 47-58.
25. Gerrard DE, Okamura CS, Grant AL. Expression and location of IGF binding proteins-2,-4, and-5 in developing fetal tissues. J Anim Sci 1999; 77: 1431-1441.
26. Green BN, Jones SB, Streck RD, Wood TL, Rotwein P, Pintar JE. Distinct expression patterns of insulin-like growth factor binding proteins 2 and 5 during fetal and postnatal development. Endocrinology 1994; 134: 954-962.
27. Lee WH, Michels KM, Bondy CA. Localization of insulin-like growth factor binding protein-2 messenger RNA during postnatal brain development: correlation with insulin-like growth factors I and II. Neuroscience 1993; 53: 251-265.
28. Wood TL, Streck RD, Pintar JE. Expression of the IGFBP-2 gene in postimplantation rat embryos. Development 1992; 114: 59-66.
29. Huynh H, Zheng J, Umikawa M, Zhang C, Silvany R, Iizuka S et al. IGF binding protein 2 supports the survival and cycling of hematopoietic stem cells. Blood 2011; 118: 3236-3243.
30. Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM et al. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res 1999; 59: 4228-4232.
31. Busund LT, Richardsen E, Busund R, Ukkonen T, Bjornsen T, Busch C et al. Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 2005; 58: 361-366.
32. Yazawa T, Sato H, Shimoyamada H, Okudela K, Woo T, Tajiri M et al. Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. Am J Pathol 2009; 175: 976-987.
33. Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, Fuller GN et al. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA 2007; 104: 11736-11741.
34. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol 2010; 12: 49-57.
35. Hsieh D, Hsieh A, Stea B, Ellsworth R. IGFBP2 promotes glioma tumor stem cell expansion and survival. Biochem Biophys Res Commun 2010; 397: 367-372.
36. Li X, Liu Y, Granberg KJ, Wang Q, Moore LM, Ji P et al. Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma. Oncogene 2014; 34: 1619-1628.
37. Lo HW, Cao X, Zhu H, Ali-Osman F. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res 2008; 14: 6042-6054.
38. Scrideli CA, Carlotti Jr CG, Mata JF, Neder L, Machado HR, Oba-Sinjo SM et al. Prognostic significance of co-overexpression of the EGFR/IGFBP-2/HIF-2A genes in astrocytomas. J Neurooncol 2007; 83: 233-239.
39. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994; 91: 7727-7731.
40. Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, Collins VP et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 1994; 9: 2313-2320.
41. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005; 11: 1462-1466.
42. Shao H, Cheng HY, Cook RG, Tweardy DJ. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 2003; 63: 3923-3930.
43. Park OK, Schaefer TS, Nathans D. In vitro activation of Stat3 by epidermal growth factor receptor kinase. Proc Natl Acad Sci USA 1996; 93: 13704-13708.
44. Lo HW, Cao X, Zhu H, Ali-Osman F. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Mol Cancer Res 2010; 8: 232-245.
45. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005; 7: 575-589.
46. Jaganathan S, Yue P, Paladino DC, Bogdanovic J, Huo Q, Turkson J. A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. PLoS One 2011; 6: e19605.
47. Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 2005; 65: 338-348.
48. Hoshino M, Fukui H, Ono Y, Sekikawa A, Ichikawa K, Tomita S et al. Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients with esophageal squamous cell carcinoma. Pathobiology 2007; 74: 15-21.
49. Xia W, Wei Y, Du Y, Liu J, Chang B, Yu YL et al. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog 2009; 48: 610-617.
50. Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 2006; 94: 184-188.
51. Wang H, Wang H, Shen W, Huang H, Hu L, Ramdas L et al. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasionenhancing genes. Cancer Res 2003; 63: 4315-4321.
52. Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005; 6: 32-43.
53. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E et al. Targeting ADAMmediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006; 10: 39-50.
54. Zheng X, Jiang F, Katakowski M, Kalkanis SN, Hong X, Zhang X et al. Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci 2007; 98: 674-684.
55. Haynik DM, Roma AA, Prayson RA. HER-2/neu expression in glioblastoma multiforme. Appl Immunohistochem Mol Morphol 2007; 15: 56-58.
56. Waage IS, Vreim I, Torp SH. C-erbB2/HER2 in human gliomas, medulloblastomas, and meningiomas: a minireview. Int J Surg Pathol 2013; 21: 573-582.
57. Torp SH, Helseth E, Unsgaard G, Dalen A. C-erbB-2/HER-2 protein in human intracranial tumours. Eur J Cancer 1993; 29A: 1604-1606.
58. Tuzi NL, Venter DJ, Kumar S, Staddon SL, Lemoine NR, Gullick WJ. Expression of growth factor receptors in human brain tumours. Br J Cancer 1991; 63: 227-233.
59. Haapasalo H, Hyytinen E, Sallinen P, Helin H, Kallioniemi OP, Isola J. c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. Br J Cancer 1996; 73: 620-623.
60. Azar WJ, Zivkovic S, Werther GA, Russo VC. IGFBP-2 nuclear translocation is mediated by a functional NLS sequence and is essential for its pro-tumorigenic actions in cancer cells. Oncogene 2014; 33: 578-588.
61. Smalheiser NR. Proteins in unexpected locations. Mol Biol Cell 1996; 7: 1003-1014.
62. Ganesan A, Zhang J. How cells process information: quantification of spatiotemporal signaling dynamics. Protein Sci 2012; 21: 918-928.
63. Kholodenko BN. Cell-signalling dynamics in time and space. Nat Rev Mol Cell Biol 2006; 7: 165-176.
64. Housden BE, Perrimon N. Spatial and temporal organization of signaling pathways. Trends Biochem Sci 2014; 39: 457-464.
65. Wiley HS. Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res 2003; 284: 78-88.
66. Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol 2014; 24: 26-34.
67. Wang Y, Pennock S, Chen X, Wang Z. Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival. Mol Cell Biol 2002; 22: 7279-7290.
68. Pennock S, Wang Z. Stimulation of cell proliferation by endosomal epidermal growth factor receptor as revealed through two distinct phases of signaling. Mol Cell Biol 2003; 23: 5803-5815.
69. Miaczynska M, Pelkmans L, Zerial M. Not just a sink: endosomes in control of signal transduction. Curr Opin Cell Biol 2004; 16: 400-406.
70. Burke P, Schooler K, Wiley HS. Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell 2001; 12: 1897-1910.
71. Brand TM, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med 2011; 12: 419-432.
72. Boerner JL, Demory ML, Silva C, Parsons SJ. Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. Mol Cell Biol 2004; 24: 7059-7071.
73. Demory ML, Boerner JL, Davidson R, Faust W, Miyake T, Lee I et al. Epidermal growth factor receptor translocation to the mitochondria: regulation and effect. J Biol Chem 2009; 284: 36592-36604.
74. Coffer PJ, Kruijer W. EGF receptor deletions define a region specifically mediating STAT transcription factor activation. Biochem Biophys Res Commun 1995; 210: 74-81.
75. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 2001; 61: 4375-4381.
76. Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeft SK et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res 2000; 60: 4926-4931.
77. Xu K, Wang L, Shu HK. COX-2 overexpression increases malignant potential of human glioma cells through Id1. Oncotarget 2014; 5: 1241-1252.
78. Yang DI, Yin JH, Mishra S, Mishra R, Hsu CY. NO-mediated chemoresistance in C6 glioma cells. Ann NY Acad Sci 2002; 962: 8-17.
79. Giannopoulou E, Ravazoula P, Kalofonos H, Makatsoris T, Kardamakis D. Expression of HIF-1alpha and iNOS in astrocytic gliomas: a clinicopathological study. In Vivo 2006; 20: 421-425.
80. Hara A, Okayasu I. Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance. Acta Neuropathol 2004; 108: 43-48.
81. Jahani-Asl A, Bonni A. iNOS: a potential therapeutic target for malignant glioma. Curr Mol Med 2013; 13: 1241-1249.
82. Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS One 2008; 3: e3769.
83. Orian JM, Vasilopoulos K, Yoshida S, Kaye AH, Chow CW, Gonzales MF. Overexpression of multiple oncogenes related to histological grade of astrocytic glioma. Br J Cancer 1992; 66: 106-112.
84. Herms JW, von Loewenich FD, Behnke J, Markakis E, Kretzschmar HA. c-myc oncogene family expression in glioblastoma and survival. Surg Neurol 1999; 51: 536-542.
85. Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol 2009; 218: 460-466.
86. Swindle CS, Tran KT, Johnson TD, Banerjee P, Mayes AM, Griffith L et al. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol 2001; 154: 459-468.
87. Kaser MR, Lakshmanan J, Fisher DA. Comparison between epidermal growth factor, transforming growth factor-alpha and EGF receptor levels in regions of adult rat brain. Brain Res Mol Brain Res 1992; 16: 316-322.
88. Kudlow JE, Leung AW, Kobrin MS, Paterson AJ, Asa SL. Transforming growth factor-alpha in the mammalian brain. Immunohistochemical detection in neurons and characterization of its mRNA. J Biol Chem 1989; 264: 3880-3883.
89. Ferrer I, Blanco R, Carulla M, Condom M, Alcantara S, Olive M et al. Transforming growth factor-alpha immunoreactivity in the developing and adult brain. Neuroscience 1995; 66: 189-199.
90. Lazar LM, Blum M. Regional distribution and developmental expression of epidermal growth factor and transforming growth factor-alpha mRNA in mouse brain by a quantitative nuclease protection assay. J Neurosci 1992; 12: 1688-1697.
91. Becher OJ, Peterson KM, Khatua S, Santi MR, MacDonald TJ. IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK. J Child Neurol 2008; 23: 1205-1213.
92. McDonald KL, O'Sullivan MG, Parkinson JF, Shaw JM, Payne CA, Brewer JM et al. IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients. J Neuropathol Exp Neurol 2007; 66: 405-417.
93. Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer 2010; 10: 59-64.
94. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
95. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
96. Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 2000; 60: 6617-6622.